Seroconversion rates and anti-HPV titres in patients with SLE at months 7 and 12 according to baseline immunosuppressive medications
| Seroconversion rate (%) | Anti-HPV titre (mMU), median (IQR) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Medications | HPV6 | HPV11 | HPV16 | HPV18 | HPV6 | HPV11 | HPV16 | HPV18 | |
| Month 7 | |||||||||
| Prednisolone | Yes | 78 | 78 | 100 | 78 | 228 (616) | 266 (1150) | 1870 (2980) | 106 (547) |
| No | 73 | 76 | 90 | 72 | 540 (1590) | 765 (2210) | 3818 (4000) | 248 (1880) | |
| p Value | >0.99 | >0.99 | 0.56 | >0.99 | 0.30 | 0.33 | 0.04 | 0.23 | |
| AZA* | Yes | 80 | 80 | 90 | 80 | 305 (855) | 401 (1540) | 1870 (3040) | 111 (591) |
| No | 68 | 72 | 94 | 67 | 246 (794) | 339 (1310) | 3140 (3180) | 110 (752) | |
| p Value | 0.48 | 0.71 | >0.99 | 0.47 | 0.51 | 0.57 | 0.35 | 0.74 | |
| MMF† | Yes | 67 | 83 | 83 | 67 | 27 (281) | 73 (858) | 211 (2100) | 32 (248) |
| No | 76 | 75 | 94 | 75 | 341 (791) | 504 (1360) | 2560 (3650) | 118 (738) | |
| p Value | 0.64 | >0.99 | 0.40 | 0.64 | 0.13 | 0.32 | 0.02 | 0.25 | |
| CNI‡ | Yes | 67 | 83 | 83 | 83 | 438 (803) | 407 (900) | 964 (2720) | 141 (680) |
| No | 76 | 75 | 94 | 72 | 269 (667) | 401 (1334) | 2563 (3850) | 111 (740) | |
| p Value | 0.64 | >0.99 | 0.40 | >0.99 | 0.99 | 0.71 | 0.10 | 0.86 | |
| HCQ | Yes | 73 | 75 | 96 | 71 | 286 (796) | 401 (1340) | 2164 (3100) | 104 (610) |
| No | 77 | 79 | 86 | 79 | 186 (1140) | 422 (1380) | 2323 (5740) | 127 (980) | |
| p Value | >0.99 | >0.99 | 0.29 | 0.72 | 0.80 | 0.82 | 0.68 | 0.50 | |
| Month 12 | |||||||||
| Prednisolone | Yes | 80 | 90 | 93 | 69 | 105 (167) | 241 (459) | 693 (915) | 60 (164) |
| No | 89 | 89 | 100 | 89 | 309 (425) | 315 (477) | 1516 (2120) | 143 (424) | |
| p Value | >0.99 | >0.99 | >0.99 | 0.40 | 0.11 | 0.46 | 0.06 | 0.26 | |
| AZA* | Yes | 90 | 90 | 95 | 75 | 120 (306) | 218 (572) | 371 (1040) | 69 (173) |
| No | 74 | 89 | 94 | 72 | 102 (292) | 261 (411) | 1000 (1300) | 63 (214) | |
| p Value | 0.24 | >0.99 | >0.99 | >0.99 | 0.40 | 0.94 | 0.22 | 0.99 | |
| MMF† | Yes | 33 | 83 | 83 | 33 | 16 (35) | 119 (457) | 478 (1150) | 14 (88) |
| No | 91 | 91 | 97 | 81 | 142 (271) | 261 (474) | 863 (1120) | 82 (190) | |
| p Value | 0.006 | 0.51 | 0.29 | 0.03 | 0.001 | 0.26 | 0.21 | 0.04 | |
| CNI‡ | Yes | 67 | 83 | 83 | 67 | 56 (165) | 228 (335) | 649 (965) | 50 (92) |
| No | 85 | 91 | 97 | 75 | 130 (255) | 255 (478) | 863 (1290) | 82 (202) | |
| p Value | 0.29 | 0.51 | 0.29 | 0.64 | 0.18 | 0.38 | 0.28 | 0.23 | |
| HCQ | Yes | 88 | 96 | 96 | 75 | 120 (180) | 247 (377) | 759 (1070) | 63 (128) |
| No | 69 | 79 | 93 | 71 | 78 (390) | 179 (618) | 891 (2830) | 69 (228) | |
| p Value | 0.19 | 0.13 | >0.99 | >0.99 | 0.83 | 0.54 | 0.44 | 0.78 | |
↵* All except three patients on AZA were receiving prednisolone in combination.
↵† All patients on MMF were receiving prednisolone in combination.
↵‡ All except one patient on CNI were receiving prednisolone in combination.
AZA, azathioprine; CNI, calcineurin inhibitors (ciclosporin A or tacrolimus); HCQ, hydroxychloroquine; HPV, human papilloma virus; MMF, mycophenolate mofetil; SLE, systemic lupus erythematosus